This technology involves the use of transcranial brain stimulation to induce sleep and has the potential to be an effective non-pharmacological approach for treating insomnia and improving sleep quantity and quality. Specifically, the technology targets the Default Mode Network (DMN) through Continuous Theta Burst stimulation, which has been shown to reduce neural activity in the part of the brain responsible for daydreaming and rumination, ultimately leading to a reduction in sleep onset time. Background: According to the American Academy of Sleep Medicine, 30-35% of adults have brief symptoms of insomnia, 15-20% have short-term insomnia disorder, which lasts less than three months, and 10% have a chronic insomnia disorder, which occurs at least three times per week for at least three months. Chronic insomnia can have a negative impact on health, increasing the risk of depression and high blood pressure, and manifests as fatigue, poor memory, inability to concentrate, mood disturbance, and/or increased errors or accidents. Current treatments for insomnia include cognitive behavioral therapy (CBT) and prescription sleeping pills. Chronic insomnia is a disorder associated with increased cognitive arousal. Insomnia is also associated with activation/connectivity within the default mode network (DMN) of the brain, consistent with the hyperarousal theory. Using transcranial stimulation toward the DMN is an effective and non-invasive method to address insomnia and sleep problems without the need for drugs or other chemicals. Applications:
Advantages: